Drug recall · December 30, 2020
Auryxia recall
Why: CGMP Deviations
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Auryxia (ferric citrate) tablets, 210 mg, 200-count bottles, Rx only, Manufactured for and distributed by: KERYX BIOPHARMACEUTICALS, INC., One Marina Park Drive, 12th Floor, Boston, MA 02210, NDC 59922-631-01
- Lots / codes
Lot Number: 9062, exp. date Feb 2021
- Quantity
- 2,170 bottles
- Company
- Akebia Therapeutics dba Keryx Biopharmaceutials, Inc, Cambridge, MA
- Distribution
- The product was distributed by two major distributors who further distributed the product nationwide and one specialty pharmacy.
- Initiated
- December 9, 2020 · Voluntary: Firm initiated
- Classified
- December 18, 2020
- Reported
- December 30, 2020
- Ended
- September 1, 2021
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Auryxia
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.